Crescent Biopharma, Inc. reported a net loss of $23.3 million for the first quarter of 2026, a significant increase from the $15.1 million loss recorded in the same period of the previous year. The company's revenue for the quarter was $1.0 million, derived from a license agreement, marking its first revenue generation since its inception. Total operating expenses rose to $25.8 million, up from $14.2 million in the prior year, primarily driven by increased research and development costs, which amounted to $17.9 million compared to $10.6 million in the previous year. General and administrative expenses also saw a rise, reaching $7.9 million, up from $3.6 million.
The company's financial position showed a decrease in cash and cash equivalents, which stood at $189.2 million as of March 31, 2026, down from $213.2 million at the end of 2025. This decline was attributed to cash used in operating activities, which totaled $8.9 million for the quarter. Crescent Biopharma's accumulated deficit increased to $195.1 million, reflecting its ongoing investment in product development and operational expansion. The company anticipates that its existing cash will be sufficient to fund operations for at least the next twelve months.
Strategically, Crescent Biopharma has made significant advancements, including the initiation of the ASCEND Phase 1/2 clinical trial for its lead product candidate, CR-001, a bispecific antibody targeting PD-1 and VEGF. The trial commenced in February 2026, with initial data expected in early 2027. Additionally, the company has entered into a partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. to develop SKB105, an integrin beta-6-directed antibody-drug conjugate, outside of Greater China. This collaboration is part of Crescent's broader strategy to build a robust oncology portfolio.
Operationally, Crescent Biopharma has focused on expanding its research and development capabilities, which has led to an increase in personnel-related expenses. The company has also been actively hiring to support its clinical trials and product development efforts. As of March 31, 2026, Crescent Biopharma had a total of 30,397,886 ordinary shares outstanding, reflecting its transition to a public company following a reverse recapitalization with GlycoMimetics, Inc. The company continues to evaluate its financial needs and may seek additional capital to support its ongoing research and development initiatives.
About CRESCENT BIOPHARMA, INC.
GlycoMimetics, Inc. is a biotechnology company specializing in glycomimetic small molecules that target carbohydrate-related biological processes. Its focus includes developing therapies for cancers and inflammatory diseases, with a pipeline centered on selectin antagonists like uproleselan. The company collaborates globally, holds key patents, and relies on third-party manufacturing, aiming to address high unmet medical needs through innovative, proprietary drug candidates.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.